Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase I open label study to asses the safety and tolerability of ZD6474 in combination with Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as first or second line therapy in patients with metastatic colorectal adenocarcinoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Camptothecin; Fluorouracil; Irinotecan; Leucovorin

Criteria

Inclusion Criteria:

1. Confirmed metastatic colorectal adenocarcinoma

2. Not amenable to surgery or radiation therapy

3. Eligible for first or second line chemotherapy

Exclusion Criteria:

1. Brain metastases or spinal compression

2. Last prior chemotherapy discontinued within 4 weeks before start

3. Last dose radiotherapy within 4 weeks of start